Filana Therapeutics, Inc. FLNA
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.06M | 3.30M | 4.54M | 3.85M | 1.29M |
| Gross Profit | -1.06M | -3.30M | -4.54M | -3.85M | -1.29M |
| SG&A Expenses | 7.41M | 6.09M | 6.62M | 5.70M | 7.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.27M | 9.39M | 11.17M | 9.55M | 11.86M |
| Operating Income | -11.27M | -9.39M | -11.17M | -9.55M | -11.86M |
| Income Before Tax | -10.73M | -8.60M | -10.33M | -12.54M | -10.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.73M | -8.60M | -10.33M | -12.54M | -10.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.73M | -8.60M | -10.33M | -12.54M | -10.81M |
| EBIT | -11.27M | -9.39M | -11.17M | -9.55M | -11.86M |
| EBITDA | -11.06M | -9.15M | -10.93M | -9.19M | -11.73M |
| EPS Basic | -0.22 | -0.18 | -0.21 | -0.26 | -0.22 |
| Normalized Basic EPS | -0.14 | -0.11 | -0.13 | -0.11 | -0.14 |
| EPS Diluted | -0.22 | -0.18 | -0.21 | -0.26 | -0.22 |
| Normalized Diluted EPS | -0.14 | -0.11 | -0.13 | -0.11 | -0.14 |
| Average Basic Shares Outstanding | 48.46M | 48.31M | 48.31M | 48.31M | 48.31M |
| Average Diluted Shares Outstanding | 48.46M | 48.31M | 48.31M | 48.31M | 48.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |